TELA Bio, Inc. Selling and Marketing Expense
TELA Bio, Inc. (TELA) reported Selling and Marketing Expense of $16.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-11
- TELA Bio, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $16.44M, a 2.46% decline year-over-year.
- TELA Bio, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $16.54M, a 0.43% decline year-over-year.
- TELA Bio, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $14.49M, a 3.82% increase year-over-year.
- TELA Bio, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $15.23M, a 7.56% decline year-over-year.
- TELA Bio, Inc. selling and marketing expense for fiscal 2025 was $63.18M, a 2.27% decline from fiscal 2024.
- TELA Bio, Inc. selling and marketing expense for fiscal 2024 was $64.65M, a 8.32% increase from fiscal 2023.
- TELA Bio, Inc. selling and marketing expense for fiscal 2023 was $59.68M, a 37.98% increase from fiscal 2022.
- TELA Bio, Inc. selling and marketing expense for fiscal 2022 was $43.25M, a 48.83% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.44M 10-Q · filed 2026-08-11 | $32.98M 10-Q · filed 2026-08-11 | $47.47M derived: sum of 3 quarters · filed 2026-08-11 | $62.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $16.54M 10-Q · filed 2026-05-13 | $31.03M derived: sum of 2 quarters · filed 2026-05-13 | $46.25M derived: sum of 3 quarters · filed 2026-05-13 | $63.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $14.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $29.72M derived: sum of 2 quarters · filed 2026-03-25 | $46.57M derived: sum of 3 quarters · filed 2026-08-11 | $63.18M 10-K · filed 2026-03-25 |
| 2025-09-30 | $15.23M 10-Q · filed 2025-11-14 | $32.08M derived: sum of 2 quarters · filed 2026-08-11 | $48.69M 10-Q · filed 2025-11-14 | $62.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $16.86M 10-Q · filed 2026-08-11 | $33.47M 10-Q · filed 2026-08-11 | $47.42M derived: sum of 3 quarters · filed 2026-08-11 | $63.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $16.61M 10-Q · filed 2026-05-13 | $30.57M derived: sum of 2 quarters · filed 2026-05-13 | $47.04M derived: sum of 3 quarters · filed 2026-05-13 | $63.74M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $13.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $30.43M derived: sum of 2 quarters · filed 2026-03-25 | $47.13M derived: sum of 3 quarters · filed 2026-03-25 | $64.65M 10-K · filed 2026-03-25 |
| 2024-09-30 | $16.47M 10-Q · filed 2025-11-14 | $33.17M derived: sum of 2 quarters · filed 2025-11-14 | $50.69M 10-Q · filed 2025-11-14 | $67.86M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | $16.70M 10-Q · filed 2025-08-11 | $34.22M 10-Q · filed 2025-08-11 | $51.38M derived: sum of 3 quarters · filed 2026-03-25 | $65.86M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | $17.52M 10-Q · filed 2025-05-08 | $34.68M derived: sum of 2 quarters · filed 2026-03-25 | $49.16M derived: sum of 3 quarters · filed 2026-03-25 | $63.73M derived: sum of 4 quarters · filed 2026-03-25 |
| 2023-12-31 | $17.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $31.64M derived: sum of 2 quarters · filed 2026-03-25 | $46.22M derived: sum of 3 quarters · filed 2026-03-25 | $59.68M 10-K · filed 2026-03-25 |
| 2023-09-30 | $14.47M 10-Q · filed 2024-11-08 | $29.05M derived: sum of 2 quarters · filed 2024-11-08 | $42.52M 10-Q · filed 2024-11-08 | $54.16M derived: sum of 4 quarters · filed 2025-03-21 |
| 2023-06-30 | $14.58M 10-Q · filed 2024-08-13 | $28.04M 10-Q · filed 2024-08-13 | $39.69M derived: sum of 3 quarters · filed 2025-03-21 | $50.86M derived: sum of 4 quarters · filed 2025-03-21 |
| 2023-03-31 | $13.47M 10-Q · filed 2024-05-10 | $25.11M derived: sum of 2 quarters · filed 2025-03-21 | $36.28M derived: sum of 3 quarters · filed 2025-03-21 | $47.34M derived: sum of 4 quarters · filed 2025-03-21 |
| 2022-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $22.82M derived: sum of 2 quarters · filed 2025-03-21 | $33.87M derived: sum of 3 quarters · filed 2025-03-21 | $43.25M 10-K · filed 2025-03-21 |
| 2022-09-30 | $11.17M 10-Q · filed 2023-11-13 | $22.23M derived: sum of 2 quarters · filed 2023-11-13 | $31.61M 10-Q · filed 2023-11-13 | $39.92M derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-06-30 | $11.05M 10-Q · filed 2023-08-10 | $20.43M 10-Q · filed 2023-08-10 | $28.75M derived: sum of 3 quarters · filed 2024-03-22 | $35.69M derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-03-31 | $9.38M 10-Q · filed 2023-05-11 | $17.69M derived: sum of 2 quarters · filed 2024-03-22 | $24.64M derived: sum of 3 quarters · filed 2024-03-22 | $32.14M derived: sum of 4 quarters · filed 2024-03-22 |
| 2021-12-31 | $8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $15.26M derived: sum of 2 quarters · filed 2024-03-22 | $22.76M derived: sum of 3 quarters · filed 2024-03-22 | $29.06M 10-K · filed 2024-03-22 |
| 2021-09-30 | $6.95M 10-Q · filed 2022-11-10 | $14.45M derived: sum of 2 quarters · filed 2022-11-10 | $20.75M 10-Q · filed 2022-11-10 | $27.13M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | $7.50M 10-Q · filed 2022-08-11 | $13.80M 10-Q · filed 2022-08-11 | $20.18M derived: sum of 3 quarters · filed 2023-03-23 | $26.52M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | $6.30M 10-Q · filed 2022-05-11 | $12.68M derived: sum of 2 quarters · filed 2023-03-23 | $19.02M derived: sum of 3 quarters · filed 2023-03-23 | $23.14M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $6.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $12.72M derived: sum of 2 quarters · filed 2023-03-23 | $16.84M derived: sum of 3 quarters · filed 2023-03-23 | $22.11M 10-K · filed 2023-03-23 |
| 2020-09-30 | $6.34M 10-Q · filed 2021-11-12 | $10.46M derived: sum of 2 quarters · filed 2021-11-12 | $15.73M 10-Q · filed 2021-11-12 | $21.12M derived: sum of 4 quarters · filed 2022-03-23 |
| 2020-06-30 | $4.12M 10-Q · filed 2021-08-12 | $9.39M 10-Q · filed 2021-08-12 | $14.77M derived: sum of 3 quarters · filed 2022-03-23 | $19.51M derived: sum of 4 quarters · filed 2022-03-23 |
| 2020-03-31 | $5.27M 10-Q · filed 2021-05-14 | $10.65M derived: sum of 2 quarters · filed 2022-03-23 | $15.39M derived: sum of 3 quarters · filed 2022-03-23 | $19.33M derived: sum of 4 quarters · filed 2022-03-23 |
| 2019-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $10.12M derived: sum of 2 quarters · filed 2022-03-23 | $14.06M derived: sum of 3 quarters · filed 2022-03-23 | $18.06M 10-K · filed 2022-03-23 |
| 2019-09-30 | $4.74M 10-Q · filed 2020-11-12 | $8.68M derived: sum of 2 quarters · filed 2020-11-12 | $12.68M 10-Q · filed 2020-11-12 | $16.69M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $3.95M 10-Q · filed 2020-08-13 | $7.94M 10-Q · filed 2020-08-13 | $11.96M derived: sum of 3 quarters · filed 2021-03-25 | $15.57M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $4.00M 10-Q · filed 2020-05-15 | $8.01M derived: sum of 2 quarters · filed 2021-03-25 | $11.62M derived: sum of 3 quarters · filed 2021-03-25 | |
| 2018-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $7.62M derived: sum of 2 quarters · filed 2021-03-25 | $13.65M 10-K · filed 2021-03-25 | |
| 2018-09-30 | $3.61M 10-Q · filed 2019-12-18 | $9.63M 10-Q · filed 2019-12-18 | ||
| 2017-12-31 | $8.71M 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| InspireMD, Inc. (NSPR) | $0.033B |